(2S,3S,4R,5R)-3-azido-5-(6-chloro-purin-9-yl)-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide | 331728-86-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S,3S,4R,5R)-3-azido-5-(6-chloro-purin-9-yl)-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide
• 英文别名: (2S,3S,4R,5R)-3-azido-5-(6-chloro-purin-9-yl)-4-hydroxy-tetrahydrofuran-2-carboxylic acid methylamide；(2S,3S,4R,5R)3-azido-5-(6-chloro-purin-9-yl)-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide；(2S,3S,4R,5R) 3-azido-5-(6-chloropurin-9-yl)-4-hydroxytetrahydrofuran-2-carboxylic acid methylamide；(2S,3S,4R,5R)-3-azido-5-(6-chloropurin-9-yl)-4-hydroxy-N-methyloxolane-2-carboxamide
• CAS: 331728-86-0
• 化学式: C₁₁H₁₁ClN₈O₃
• 分子量: 338.713
• InChiKey: KUCQALFRIFPHNR-ZCRVCMQPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  117
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (2S,3S,4R,5R)-3-azido-5-(6-chloro-purin-9-yl)-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide 在 ammonium hydroxide 、 水 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 20.0h， 生成 CP-608039
  参考文献：
  名称：

  3‘-Aminoadenosine-5‘-uronamides:  Discovery of the First Highly Selective Agonist at the Human Adenosine A₃ Receptor

  摘要：

  Selective adenosine A(3) agonists have potential utility for the prevention of perioperative myocardial ischemic injury. Herein, we report on the discovery and synthesis of compound 7. This amino nucleoside agonist possesses unprecedented levels of selectivity for the human adenosine A(3) receptor.

  DOI：

  10.1021/jm0255724
• 作为产物：
  描述：

  双丙酮葡萄糖 在 ruthenium trichloride 吡啶 、 sodium periodate 、 sodium azide 、 草酰氯 、 三氟甲磺酸三甲基硅酯 、 硫酸 、 过碘酸 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二氯甲烷 、 氯仿 、 水 、 溶剂黄146 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 104.0h， 生成 (2S,3S,4R,5R)-3-azido-5-(6-chloro-purin-9-yl)-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide
  参考文献：
  名称：

  3‘-Aminoadenosine-5‘-uronamides:  Discovery of the First Highly Selective Agonist at the Human Adenosine A₃ Receptor

  摘要：

  Selective adenosine A(3) agonists have potential utility for the prevention of perioperative myocardial ischemic injury. Herein, we report on the discovery and synthesis of compound 7. This amino nucleoside agonist possesses unprecedented levels of selectivity for the human adenosine A(3) receptor.

  DOI：

  10.1021/jm0255724

文献信息

• Compounds for the treatment of ischemia
  申请人：——

  公开号：US20040198693A1

  公开（公告）日：2004-10-07

  A 3 agonists, methods of using such A 3 agonists and pharmaceutical compositions containing such A 3 agonists. The A 3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia.

  A3激动剂，使用此类A3激动剂的方法以及含有此类A3激动剂的药物组合物。这些A3激动剂对于减少由组织缺血或缺氧引起的组织损伤是有用的。
• The synthesis of highly potent, selective, and water-soluble agonists at the human adenosine A3 receptor
  作者：Michael P. DeNinno、Hiroko Masamune、Lois K. Chenard、Kenneth J. DiRico、Cynthia Eller、John B. Etienne、Jeanene E. Tickner、Scott P. Kennedy、Delvin R. Knight、Jimmy Kong、Joseph J. Oleynek、W. Ross Tracey、Roger J. Hill

  DOI：10.1016/j.bmcl.2006.01.088

  日期：2006.5

  Using a combination of parallel and directed synthesis, the discovery of a highly potent and selective series of adenosine A3 agonists was achieved. High aqueous solubility, required for the intended parenteral route of administration, was achieved by the presence of one or two basic amine functional groups.

  使用平行和定向合成的组合，发现了高效和选择性系列的腺苷A3激动剂。预期的肠胃外给药途径所需的高水溶性是通过存在一个或两个碱性胺官能团实现的。
• [EN] COMPOUNDS FOR THE TREATMENT OF ISCHEMIA<br/>[FR] COMPOSES DESTINES AU TRAITEMENT D'ISCHEMIE
  申请人：PFIZER PROD INC

  公开号：WO2001023399A1

  公开（公告）日：2001-04-05

  A3 agonists, methods of using such A3 agonists and pharmaceutical compositions containing such A3 agonists. The A3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia.

  A3激动剂，使用这种A3激动剂的方法和含有这种A3激动剂的药物组合物。这些A3激动剂对于减少组织缺血或低氧引起的组织损伤非常有用。
• Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same
  申请人：Fukutomi Ryuuta

  公开号：US20050085508A1

  公开（公告）日：2005-04-21

  There are provided novel 4-(2-furoyl)aminopiperidines represented by the general formula (I), their synthetic intermediates, processes for their preparation and medicaments containing them. In the above formula, X is CH or N, and Y is a group of the following general formula (II), formula (II-a) or formula (III): wherein a, b and c are each an integer of 0-6; Z is CH 2 or NH; W is O or S; T is O or N—R 15 wherein R 15 is H, a C1-C6 alkyl group, a benzyl group or a phenethyl group; and R 1 is H, a C1-C6 alkoxycarbonyl group, a benzyloxycarbonyl group, or the like. The 4-(2-furoyl)aminopiperidine derivatives according to this invention possess opioid μ antagonistic activity and are useful for the treatment or prevention of side effects which are caused by μ receptors agonist and which are selected from constipation, nausea/emesis or itch, or for the treatment or prevention of idiopathic constipation, postoperative ileus, paralytic ileus, irritable bowel syndrome or chronic pruritus.

  提供了一种新的4-(2-呋喃酰基)氨基哌啶化合物，其通式表示为(I)，以及它们的合成中间体、制备过程和含有它们的药物。 在上述式中，X为CH或N，Y为以下通式(II)、式(II-a)或式(III)的基团： 其中a、b和c均为0-6的整数；Z为CH2或NH；W为O或S；T为O或N—R15，其中R15为H、C1-C6烷基、苄基或苯乙基；R1为H、C1-C6烷氧羰基、苄氧羰基或类似基团。本发明所述的4-(2-呋喃酰基)氨基哌啶衍生物具有阿片μ受体拮抗活性，可用于治疗或预防由μ受体激动剂引起的副作用，包括便秘、恶心/呕吐或瘙痒，或用于治疗或预防特发性便秘、术后肠梗阻、麻痹性肠梗阻、肠易激综合征或慢性瘙痒。
• Purine derivatives for the treatment of ischemia
  申请人：Pfizer Products Inc.

  公开号：EP1241176A1

  公开（公告）日：2002-09-18

  A3 agonists having Formula I are described herein as well as methods of using such A3 agonists and pharmaceutical compositions containing such A3 agonists. The A3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia.

  本文描述了具有式 I 的 A3 激动剂以及使用这种 A3 激动剂的方法和含有这种 A3 激动剂的药物组合物。 A3 激动剂可用于减少组织缺血或缺氧造成的组织损伤。